| | Call Details | OBAGI MEDICAL PRODUCTS INC Earnings Conference Call (Q1 2008) Mon,
May 5, 2008, 4:30 pm Eastern
| | About OBAGI MEDICAL PRODUCTS INC
(NasdaqGS:OMPI) |
| | Obagi Medical Products, Inc., a specialty pharmaceutical company, develops and markets skincare products in the United States and internationally. It develops and commercializes prescription-based, topical skin health systems, which enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyper-pigmentation, and acne, as well as soft tissue deficits, such as fine lines and wrinkles. The company offers Obagi Nu-Derm System, a prescription-based, topical skin health system on the market that has been shown to enhance the skins overall health by correcting photo-damage at the cellular level; Obagi-C Rx System, a combination of prescription and OTC drugs and adjunctive cosmetic skin care products to treat skin conditions resulting from sun damage and the oxidative damage of free radicals; and Obagi Professional-C products, a line of proprietary, non-prescription products, which consist of Vitamin C serums used to reduce the appearance of damage to the skin caused by ultraviolet radiation and other environmental influences. It also offers Obagi Condition and Enhance System for use in conjunction with commonly performed cosmetic procedures, including Botox injections; ELASTIderm product line, an eye cream for improving the elasticity and skin tone around the eyes; CLENZIderm product line for addressing acne and skin elasticity; and tretinoin, used for the topical treatment of acne in the United States, and Obagi Blue Peel products, used to aid the physician in the application of skin peeling actives. The company markets its products through its domestic sales force and foreign distribution partners to plastic surgeons, dermatologists, and other physicians that are focused on aesthetic and therapeutic skin care. Obagi Medical Products, Inc. was founded in 1988 and is headquartered in Long Beach, California. |
| More
Info:
Quote
|
Profile
|
Reports
|
Research
|
Insider
|
Financials
|
Analyst Ratings |
|